cyrilzakka/clinical-trials huggingface dataset:
Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata

Alopecia Areata is a common condition. This study investigated the efficacy of calcipotriol versus Narrow Band Ultraviolet B in treatment of Alopecia areata and their effects on serum vitamin D3 levels.


Eligibility Criteria:
Inclusion Criteria:

* Alopecia Areata of scalp

Exclusion Criteria:

Other causes of alopecias including scarring alopecia, androgenic alopecia, telogen effluvium autoimmune diseases, pregnant and lactating females
Epidemiology of Respiratory Insufficiency in Critical Care

Acute respiratory failure is a common entity in intensive care units nowadays and is associated with significant morbidity and mortality, thus representing a major health problem. Most of the published epidemiological studies on this condition were performed when modern ventilatory strategies and non-invasive ventilation were not available. Therefore, an actual evaluation on the incidence and outcomes of this syndrome is mandatory. We will perform an observational prospective study of patients admitted with acute respiratory insufficiency in several ICUs in Brazil.


Eligibility Criteria:
Inclusion Criteria:

* Need for non-invasive or invasive mechanical ventilation for more than 24 hours in the first 48 hours of admission to the intensive care unit.

Exclusion Criteria:

* Tracheostomized patients
* Patients admitted to ICUs for monitoring or in post-operatory of non-complicated surgeries.
* Patients with cancer on terminal stage.
The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors

This phase I study will examine the pharmacokinetics and safety of Onartuzumab (MetMAb) in chinese patients with locally advanced or metastatic solid tumors. Patients will be divided into 3 cohorts, which will each be given a different dose of MetMAb. The cohorts will be treated sequentially, starting with the lowest dose. MetMAb will be administered intravenously every 3 weeks. Patients may be treated for up to 16 cycles (21 days each) or 1 year, whichever occurs first, in the absence of disease progression.


Eligibility Criteria:
Inclusion Criteria:

* Age \>/= 18 years
* Histologically confirmed locally advanced or metastatic solid tumor that does not respond to standard treatment or for which there is no further standard treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
* Use of effective contraception
* Life expectancy \> 3 months

Exclusion Criteria:

* Brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation, and/or patients with brain metastasis that have been receiving corticosteroids.
* Previously diagnosed and treated central nervous system (CNS) metastases or spinal cord compression that has not been clinically stable for at least 2 months.
* Treatment with anti-tumor therapy within 4 weeks before the start of study treatment, with the following exception: Patients with metastatic prostate cancer on maintenance hormonal therapy, provided they meet all other eligibility criteria.
* Current, serious or uncontrolled, systemic illness.
* Recent stroke (within the past 6 months).
* Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs).
* History of cardiovascular conditions.
* Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
* Receipt of any investigational agent, or participation in any other clinical study, within 4 weeks before the start of study treatment.
* Major surgery within 4 weeks before the start of study treatment, without complete recovery.
* Significant traumatic injury within 3 weeks before the start of study treatment (All wounds must be fully healed prior to Day 1).
* Uncontrolled excess calcium levels.
* Known human immunodeficiency virus (HIV) infection.
* Inadequate organ function
* Pregnancy
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors

This is a Phase 1, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-07062119 administered as a single agent in sequential dose levels and then in combination with anti-programmed cell death -1 protein (anti-PD-1) and in combination with an anti-vascular endothelial growth factor (anti-VEGF). In Part 1A, successive cohorts of patients will receive escalating doses of PF-007062119 and then in dose finding (Part 1B) with PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF. This study contains 2 parts, dose escalation with single agent (Part 1A) and then dose finding with PF-007062119 in combination with ant-PD-1 and in combination with anti-VEGF (Part 1B) followed by dose expansion arms as a single agent and PF-07062119 in combination with anti-PD 1 and in combination with anti-VEGF (Part 2).

Eligibility Criteria:
Inclusion Criteria:

* For Part 1 and Part 2, diagnosis of advanced/metastatic colorectal, gastric or esophageal adenocarcinoma that is resistant to standard therapy or for which no local regulatory approved standard therapy is available that would confer significant benefit.
* For Part 2, diagnosis of colorectal adenocarcinoma that is resistant to standard therapy or for which no standard therapy is available
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
* Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
* Measurable disease as defined by RECIST 1.1 is required (Part 2)

Exclusion Criteria:

* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
* Major surgery or radiation within 3 weeks prior to study entry
* Last anti-cancer treatment within 4 weeks prior to study entry
* Active or history of clinically significant autoimmune disease that required systemic immunosuppressive medication
* Active or history of clinically significant gastrointestinal disease
* Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry
* Pregnant or breastfeeding female patients
FACBC PET/CT for Recurrent Prostate Cancer

Hypothesis:Anti-\[18F\]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients.

This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called \[18\]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called \[18\]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called \[18\]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done.

Anti-\[18F\]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention.

This study will look at how the \[18\]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.


Eligibility Criteria:
STUDY NOW CLOSED for recruitment

Inclusion Criteria:

* Patients must be 18 years of age or older.
* Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 ) prostate carcinoma and have undergone what was considered definitive therapy for localized disease.
* In the case of brachytherapy, cryotherapy, or external beam radiation, treatment will have occurred at least 2 years in the past to eliminate patients with so-called "PSA bump."
* Patient will have suspicion of recurrent prostate carcinoma as defined by: ASTRO criteria of three consecutive rises of PSA or earlier if clinically appropriate, and/or nadir + 2.0 after radiotherapy, and/or greater than 0.3 after prostatectomy.
* Ability to lie still for PET scanning
* Patients must be able to provide written informed consent.

Exclusion Criteria:

* Age less than 18.
* Greater than T3 disease in past
* Prior prostatectomy or 2 years since brachytherapy, cryotherapy, or external beam radiation therapy.
* Does not meet above criteria of suspicious PSA elevation
* Inability to lie still for PET scanning
* Cannot provide written informed consent.
* Bone scan findings characteristic for metastatic prostate carcinoma
* Less than 2 months since any prior prostate biopsy (to decrease false positive uptake from inflammation).
Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa

The investigators will recruit individuals with broadly-defined AN (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization/day treatment, intensive outpatient treatment). Interested participants will sign consent, complete eligibility assessments, and will be randomized to receive Positive Affect Treatment for Anorexia Nervosa (PAT-AN) or Psychoeducation and Behavioral Therapy (PBT) through teletherapy shortly following discharge from higher level of care. Participants can participate in most other forms of outpatient treatment while receiving the research intervention. Participants will engage in 24 weeks of PAT-AN or PBT starting in the first 3 months post-discharge. At each session, the investigators will complete brief measures assessing treatment acceptability, affect, and eating disorder symptoms. Participants will also complete an assessment battery of self-report, EMA, and neurocognitive measures evaluating primary outcomes (BMI; eating disorder symptoms), secondary outcomes (depression, anxiety, and suicidality), and presumed treatment mechanisms at baseline, end of treatment (EOT), and 3-month follow-up (FU). All assessments will be remotely delivered via HIPAA-compliant platforms.


Eligibility Criteria:
Inclusion Criteria:

1. Age \> or = 18 years old
2. Ability to read and speak in English
3. DSM-5 diagnosis of AN or atypical AN at admission to higher-level care
4. In higher-level care discharging to outpatient care or discharged to outpatient care within the past 3 months
5. Current BMI \> or = 18.5 kg/m2 (or will be by time of discharge)
6. BMI increase of \> or = 0.5 kg/m2 while in higher-level care
7. Ability to designate and sign a release of information for a primary physical or mental health provider for study duration
8. Willingness to participate in weekly assessments (e.g., weight monitoring) and audio or video recording of study therapy sessions for study duration
9. Access to a smartphone and/or computer permitting engagement in remote therapy and assessment.

Exclusion Criteria:

1. Medical instability for outpatient care;
2. Pregnancy
3. Lifetime DSM-5 primary psychotic or bipolar-I disorder
4. Current DSM-5 substance use disorder
5. Enrollment in outpatient therapy with highly overlapping content to PAT-AN
Bilateral Uterine Artery Ligation During the Cesarean Delivery of Twins

Objective to assess the effectiveness of prophylactic bilateral uterine artery ligation (BUAL) in reducing the incidence of postpartum hemorrhage during cesarean delivery among women with twin pregnancy

A randomized clinical trial at Aswan University Maternity Hospital, Egypt. Women with twin pregnancy undergoing scheduled or emergency cesarean were randomized into two groups. In the BUAL group, women underwent BUAL before placental delivery; in the control group, women had cesarean delivery without BUAL. The primary outcome was the estimated blood loss during a cesarean

Eligibility Criteria:
Inclusion Criteria:

* women undergoing cesarean section
* twin pregnancy

Exclusion Criteria:

* Placenta previa.
* Ante-partum hemorrhage.
* patient refuse to participate
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.

The study is a randomized, double-blind phase 1 trial including 2 sequential parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part. SAD and MAD are dose-escalated tolerant study designing. The aims of the study as below:

1. Evaluating the safety and tolerance of ZG0418 in ALK+ NSCLC.
2. Evaluating the fasting pharmacokinetic parameters of ZG0418 in ALK+ NSCLCJaktinib.
3. Evaluating the postprandial pharmacokinetic parameters of ZG0418 in ALK+ NSCLC.
4. Analysis the metabolites of ZG0418

Eligibility Criteria:
Inclusion Criteria:

1. Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib
2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.
3. Life expectancy of at least 12 weeks.
4. Ability to swallow and retain oral medication.
5. Adequate organ system function, defined as follows:

   1. Absolute neutrophil count (ANC) ≥1.5 x 10\^9/L
   2. Platelets ≥75 x 10\^9/L
   3. Hemoglobin ≥9 g/dL (≥90 g/L) Note that transfusions are allowed to meet the required hemoglobin level
   4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)
   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

      ≤2.5 x ULN if no liver involvement or ≤5 x ULN with liver involvement.
   6. Creatinine 1.5 x ULN.
6. Brain metastases allowed if asymptomatic at study baseline.
7. Patients must have measurable disease per RECIST v. 1.1.

Exclusion Criteria:

1. chemotherapy, radiation therapy, immunotherapy within 4 weeks.
2. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
3. uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion.
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).


Eligibility Criteria:
Main Inclusion Criteria:

* FEV1/FVC ratio (post-bronchodilator) ≤70%
* FEV1 (post-bronchodilator) ≤50% of predicted
* Current smoker or ex-smoker
* Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline
* Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit B0 or a willingness to have a chest x-ray performed before baseline

Main Exclusion Criteria:

* COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline
* Lower respiratory tract infection not resolved 4 weeks prior to baseline
* Diagnosis of asthma and/or other relevant lung disease
* Known alpha-1-antitrypsin deficiency
* Need for long-term oxygen therapy defined as ≥16 hours/day
Contribution of Hypnosis During a Lumbar Puncture.

The purpose of this study is to assess the effect of hypnosis, as add on therapy, on patients requiring a lumbar puncture (LP) as part of their medical management.

This study will follow the zelen's methodology randomization. It is an add-on study design.

1. The study will be presented to patients as an assessment of their comfort during the LP. The intervention group is not presented to the patient.
2. Patients are asked to sign the consent of the standard of care group.
3. Randomization into two equally sized groups:

   * Intervention arm : LP with complementary hypnoanalgesia
   * Control arm : LP without complementary hypnoanalgesia
4. Patients who have been randomized into the control group, will have LP according to the standard of care.

Patients who have been randomized into the hypnoanalgesic group will be informed about the hypnoanalgesia intervention and then asked to sign the consent of the hypnosis group.

* if the patient accepts, he will benefit from hypnosis during LP.
* if the patient refuses, he will re-join the control group without hypnosis.

The physicians performing LP will be the same in both groups. A phone call follow-up is scheduled on day 3 and 7 after intervention.

Eligibility Criteria:
Inclusion Criteria:

* Required a lumbar puncture for diagnosis
* Affiliated with social security system
* Patient's written consent

Exclusion Criteria:

* LP contraindication
* History of previous LP
* Psychiatric disorder making the realization of a hypnosis irrelevant
* Cognitive-behavioural abilities that do not allow the completion of the study
* Persons who are protected under the act. Person deprived of liberty by judicial decision
* Pregnant or Breastfeeding woman
Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear

Anterior cruciate ligament (ACL) tear is frequent, but the diagnosis of partial tears is difficult. Standard MRI may be used but is of limited diagnostic value. The present study aimed to evaluate the diagnostic interest of dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear.


Eligibility Criteria:
Inclusion Criteria:

* knee injury requiring MRI examination
* accepting to participate
* covered by a health care insurance system

Exclusion Criteria:

* MRI contraindication
* pregnancy
* patient included in another study potentially affecting the results
* protected patients
Trabecular Bone Score in Multiple Sclerosis

Assess bone quality in MS patients through TBS and evaluate the potential effects exerted by different drugs used in MS treatment, which may affect BMD and TBS in MS patients


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of MS according to the latest revision of McDonald's criteria;
* patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (SPMS);
* absence of cortisone therapy for at least 6 months;

Exclusion Criteria:

patients already being treated with anti-osteoporotic drugs;

• medical conditions that preclude the execution of the densitometric examination
Chronic Obstructive Pulmonary Disease Endpoints Study

This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.

Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol 500/50mcg combination (FSC 500/50) and its individual components, Fluticasone Propionate 500mcg (FP500) and Salmeterol 50mcg (SAL 50)

Eligibility Criteria:
Inclusion criteria:

* Diagnosis of COPD
* Current or ex-smoker at least 10 pack- years

Exclusion criteria:

* Diagnosis of asthma
* Active respiratory disorder other than COPD
* Evidence of clinically significant uncontrolled non-pulmonary disease
* Carcinoma not in complete remission for last 5 years
* Lung volume reduction surgery in previous 12 months
* Nocturnal positive pressure for sleep apnea
* Other inclusion and exclusion criteria will be evaluated at the first study visit.
Impact of Outreach on Medicaid Enrollment

This project will assess the impact of various forms of outreach from navigators on Medicaid enrollment. Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The investigators propose to randomize the nature of outreach to households in Wisconsin enrolled in fee-for-service Medicaid who must renew or lose their coverage.

During the COVID-19 public health emergency, states received support to maintain continuous Medicaid coverage, raising Medicaid enrollment to unprecedented levels. In Wisconsin, enrollment was nearly 30% higher by the end of 2021 compared to February 2020, with the maintenance of enrollment policy contributing to much of this increase. After the end of the public health emergency, normal renewal processes will resume.

The Wisconsin navigator program, Covering Wisconsin, has been commissioned by the Department of Health Services (DHS) to conduct outreach to the group of fee-for-service Medicaid beneficiaries who need to re-determine eligibility after the conclusion of the public health emergency. To identify what outreach strategies are most effective, the investigators propose to randomize the nature of outreach used. While there will be some variation in the content and timing of messages, all beneficiaries will receive messages with clear information on how to contact the navigators.

Per a protocol amendment approved on 2/21/24, the study team will no longer randomize receipt of an outbound call but rather will provide it to all participants.

Eligibility Criteria:
Inclusion Criteria:

* Included on the lists Wisconsin DHS provides to Covering Wisconsin of fee-for-service Medicaid beneficiaries who need to renew their Medicaid coverage

Exclusion Criteria:

* Prefer a language other than English or Spanish or lack a cellular phone number
Almond Milk With Vitamin D: Impact on Vitamin D Status

The overall goal is to enhance vitamin D status in a safe and effective manner. A 3-week randomized comparator-controlled trial among a cohort of adults with CKD (stages 3-5) (n=24) will test the main objective: Evaluate the bioefficacy of D3 in micro- and nanoparticles (4000IUs) in almond milk with the sub-objective of: Explore the effect of D3 in micro- and nanoparticles (4000IUs) in almond milk on inflammation markers CRP, TNF-α and IL-6.


Eligibility Criteria:
Inclusion Criteria:

* adults who have been diagnosed with CKD
* have no GI disorders or GI disturbances
* age 18 years or older
* no food allergies or dietary restrictions
* all with no contraindications to consuming anything by mouth as per their physician

Exclusion Criteria:

* no diagnosis of CKD
* GI disorders
* gastrointestinal disturbances
* under 18 years old
* food allergies to almonds
* Dietary restrictions as medically indicated
* trouble chewing/swallowing as confirmed by physician